Stereotactic body radiotherapy with functional treatment planning in hepatocellular carcinoma

Alexander Kirichenko, Eugene J. Koay, Shaakir Hasan, Christopher Crane

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related death in the United States, and considered an aggressive tumor with mean survival estimated between 6 and 20 months (El-Serag, NEJM 365:1118–1127, 2011). The choice of curative liver resection is limited by the presence of hepatic cirrhosis in 90% of patients, and the most appropriate therapy for HCC has historically been hepatic transplantation with 5-year survival rate of up to 85%. However, only 10% of patients are eligible for surgery (Fortune et al., J Clin Gastroenterol 47:S37–S42, 2013). We discuss functional treatment planning for patients with hepatic cirrhosis and HCC and present an argument in favor of liver SBRT as a viable option.

Original languageEnglish (US)
Title of host publicationMedical Radiology
Number of pages8
StatePublished - Jan 1 2018

Publication series

NameMedical Radiology
ISSN (Print)0942-5373
ISSN (Electronic)2197-4187

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Stereotactic body radiotherapy with functional treatment planning in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this